The Dutch startup ecosystem continues to captivate international attention. The State of Dutch Tech 2024 report reveals that in 2023, acquisitions in the Dutch startup ecosystem saw a notable increase ...

Today’s news follows the previous arrivals of 18 other senior leaders announced in June and Klick Media President Ray Rosti in July, highlighting the company’s continued commitment to delivering ...

M-Trust™ is a secure cyber-physical trust platform that enables the creation of digital twins for enhanced product quality ...

DARMSTADT, Germany, Jan. 6, 2025 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

UPDATED: Thursday, Jan. 2 at 1:45pm ET Shortly before the new year, Merck & Co. scored an approval for its potential blockbuster Winrevair in the U.K. The pulmonary arterial hypertension (PAH ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024, despite challenges with other products. Promising future developments include ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

In a day that already included discontinuations from Roche and Foghorn Therapeutics, Merck & Co. rounded out Monday by announcing the termination of two late-stage cancer assets. The New Jersey ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...